Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOHN W. who wrote (1985)	10/1/1997 9:32:00 PM
From: Henry Niman	of 6136

Dr. Henry reported that 4 of 7 patients (not naive) treated with Viracept failed treatment with a second PI and their baseline viral load at the time of the switch was higher than that reported in the LB-5 paper (263,027 in AGPH study; 99,600 in LB-5 paper). (from AGPH press release): "Dr. Henry will also report that viral load fell below 500 copies/mL in three of seven patients in a second group of extensively pre-treated patients (all of those tested were resistant to 3TC) from another VIRACEPT clinical trial who were switched to the regimen containing ritonavir, saquinavir, d4T and 3TC. At baseline, the mean viral load in these seven patients was 263,027; mean CD4+ T cell count was 65.(3) " I had posted this yesterday: techstocks.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next